A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Insulin resistance is blunted cellular response to insulin due to defects in insulin receptor signaling, glucose transporter translocation, or post-receptor kinase cascades. Compensatory hyperinsulinemia develops to maintain euglycemia, but progressive beta cell exhaustion and lipotoxicity lead to overt hyperglycemia and type 2 diabetes.
From your study of carbohydrate metabolism, you know the normal sequence: dietary carbohydrates raise blood glucose, the pancreatic beta cells release insulin, and insulin signals peripheral tissues — especially muscle, liver, and adipose — to take up glucose. The molecular mechanism at the cell surface is a cascade: insulin binds its receptor, activating the receptor's intrinsic tyrosine kinase, which phosphorylates IRS-1 (insulin receptor substrate-1), activating PI3K, then Akt, which ultimately causes GLUT4 glucose transporters to translocate from intracellular vesicles to the plasma membrane. GLUT4 opening is the actual portal through which glucose enters the cell. Insulin resistance is a defect anywhere in this cascade that blunts the GLUT4 response to insulin.
The molecular mechanisms are multiple. Excess intracellular fatty acids and their derivatives (diacylglycerol, ceramides) activate serine/threonine kinases — particularly PKC isoforms — that phosphorylate IRS-1 at inhibitory serine residues rather than activating tyrosine residues. This effectively jams the first relay in the signaling chain. Chronic low-grade inflammation, characteristic of obesity, contributes through TNF-α and IL-6 secreted by adipose tissue macrophages, which also activate inhibitory serine kinases. Endoplasmic reticulum stress and mitochondrial dysfunction in chronically nutrient-overloaded cells add further impairment. The end result is that even with normal circulating insulin, the GLUT4 translocation response is blunted — cells behave as if insulin concentration is lower than it actually is.
The pancreatic response is compensatory hyperinsulinemia. From your knowledge of cell signaling and feedback loops, you can predict this: if the signal is attenuated, the sender turns up the volume. Beta cells detect the persistent post-meal hyperglycemia and increase insulin secretion — sometimes to 2–5 times normal levels — to force enough receptor activation to achieve adequate glucose uptake. For years or even decades, this compensation maintains near-normal fasting glucose. Blood glucose looks controlled; the disease is invisible to routine screening. But the beta cells are working at extraordinary capacity, and the high insulin levels themselves drive further metabolic pathology: hepatic lipogenesis, triglyceride synthesis, sodium retention, and suppression of lipolysis in fat-rich adipocytes.
The transition to type 2 diabetes occurs when beta cell compensation fails. Progressive lipotoxicity — the accumulation of toxic lipid intermediates within beta cells themselves — impairs insulin secretion and triggers beta cell apoptosis. Glucotoxicity compounds this: chronically elevated glucose generates reactive oxygen species that damage beta cell mitochondria. As secretory capacity declines below what is needed to compensate for peripheral resistance, post-meal glucose spikes persist and fasting glucose eventually rises. By clinical diagnosis, most patients have already lost 50% of their beta cell mass — highlighting how late in the pathophysiological sequence the disease becomes detectable by standard criteria.
The clinical implications of this framework are important for understanding therapeutic targets. Metformin reduces hepatic glucose output (addressing the liver's failure to suppress gluconeogenesis when insulin is present). Thiazolidinediones sensitize PPAR-gamma in adipose tissue, reducing the fatty acid release that feeds inhibitory lipid metabolites into the signaling pathway. GLP-1 agonists and DPP-4 inhibitors amplify glucose-dependent insulin secretion and reduce glucagon. Each class targets a different node in the insulin resistance-hyperinsulinemia-beta cell failure sequence, which is why combination therapy is often necessary at advanced stages.